| UNIQURE N.V. EO -,05 |
| Niederlande |
| Gesundheit |
| NL0010696654 / A1XDTV |
| UQ1 (Frankfurt) / QURE (NASDAQ) |
| FRA:UQ1, ETR:UQ1, UQ1:GR, NASDAQ:QURE |
| - |
| https://www.uniqure.com/ |
|
uniQure N.V. is a biopharmaceutical company focused on gene therapy for patients with severe genetic and other serious diseases. Its current portfolio includes HEMGENIX for hemophilia B and a pipeline of investigational therapies aimed at disorders s..
>Volltext.. |
| 1398.96 Mio. EUR |
| 1172.7 Mio. EUR |
| 16.67 Mio. EUR |
| -169.32 Mio. EUR |
| -225.17 Mio. EUR |
| -3.61 EUR |
| 492.96 Mio. EUR |
| 368.74 Mio. EUR |
| -145.5 Mio. EUR |
| 9.72 |
| 34.33% |
| -30.73% |
| - |
| - |
| - |
| - |
| UNIQURE |
| 12.10.26 |
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|